Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2019-10-15 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
广东海派律师事务所关于公司2019年度非公开发行A股股票的补充法律意见书（一）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding Shenzhen Haier Bioengineering Co., Ltd.'s 2019 non-public issuance of A shares. It includes extensive legal analysis of administrative penalties, compliance with drug production and operation quality standards (GMP and GSP), and verification of the legitimacy of the funding source for the share subscription. The document references regulatory feedback from the China Securities Regulatory Commission and provides detailed legal opinions and confirmations related to the issuance process. It is not a financial report, earnings release, or management discussion, but a legal opinion related to a capital raising event (non-public share issuance). Therefore, the document is best classified as a Capital/Financing Update (CAP), as it pertains to the legal aspects of a financing activity (non-public share issuance). The document length (15,000 characters) and content confirm it is a substantive legal opinion, not a brief announcement or certification, so it is not RNS or RPA.
2019-10-15 Chinese
关于非公开发行股票申请文件反馈意见回复的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding their response to feedback from the China Securities Regulatory Commission (CSRC) on their application for a non-public issuance of shares. It discusses the submission of written replies to regulatory feedback and the ongoing approval process. The document is short (840 characters) and primarily serves as a regulatory update about the status of a capital raising process, not the actual issuance or detailed financial data. It does not contain financial statements or detailed report content but is an announcement related to capital raising and regulatory compliance. Therefore, it fits best under Capital/Financing Update (CAP).
2019-10-15 Chinese
关于深圳海王集团股份有限公司不减持公司股票承诺的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by Shenzhen Haiwang Bioengineering Co., Ltd. regarding a commitment by its controlling shareholder not to reduce its shareholding in the company. It references a non-public stock issuance plan approved at a shareholders' meeting and includes a formal pledge letter about shareholding behavior. The document is short (844 characters) and focuses on shareholding commitments rather than financial results or detailed reports. It does not contain financial statements or detailed financial data. This fits the category of Share Issue/Capital Change announcements, as it relates to a non-public stock issuance and shareholder commitments tied to that issuance.
2019-10-15 Chinese
2019年第四次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and validity of the procedures, attendance, and voting results of the 2019 fourth extraordinary general meeting (临时股东大会) of Shenzhen Haier Bioengineering Co., Ltd. It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or financial performance data, nor is it an announcement of financial results or a report on management or governance practices. It is a legal opinion on the conduct of a shareholders' meeting, which is closely related to the declaration of voting results and voting rights announcements. Therefore, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4504 characters, which is sufficient to be the actual legal opinion document rather than a brief announcement or notice. Hence, it is not an RPA or RNS filing.
2019-10-14 Chinese
第八届董事局第二次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement from Shenzhen Haier Bioengineering Co., Ltd. regarding resolutions passed at the company's eighth board of directors second meeting held on October 14, 2019. It details the appointment of senior management positions including the president, financial director, board secretary, vice presidents, and securities affairs representative. It also includes voting results and resumes of the appointed individuals. The content focuses on changes in the company's board and senior management personnel, with no financial statements or earnings data presented. The document length is 5621 characters, which is sufficient for a detailed announcement but does not constitute a full financial report. Therefore, this document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2019-10-14 Chinese
独立董事关于第八届董事局第二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the appointment and remuneration of senior management. It references compliance with company law, stock exchange listing rules, and company articles of association. The content focuses on governance matters related to board decisions and management appointments, rather than financial results, audit, or regulatory filings. It is not a full report but a governance-related statement. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2019-10-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.